Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Vidal

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Dermatologic Therapy|September 29, 2022
Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: Multicenter analysis in daily clinical practice by the Spanish Psoriasis GroupVicenç Rocamora, Laura Crespi, Marta Ferran, et al.
International Journal of Molecular Sciences|February 27, 2026
Clinical Characteristics and Gene Expression of JAK2, STAT3, miRNA-155, and miRNA-216a in Young Adults with Acute Ischemic StrokeDavid Vidal-González, Jazmin Marquez-Pedroza, Betsabé Contreras-Haro, et al.
Dermatology and Therapy|April 21, 2026
Real-World Use of Baricitinib in Patients with Atopic Dermatitis in Spain: DAMA-S Study, A Retrospective Chart ReviewEnrique Gómez de la Fuente, Enrique Herrera, Iñigo Martinez-Espronceda Esquerdo, et al.
Dermatologic Therapy|November 25, 2021
Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis GroupElena Del Alcázar, Anna López-Ferrer, Álvaro Martínez-Doménech, et al.
International Journal of Dermatology|May 13, 2024
Certolizumab pegol effectiveness, survival and safety in patients with psoriasis: A multicenter retrospective analysis in daily clinical practice by the Spanish Psoriasis GroupAntonio Sahuquillo-Torralba, Miguel Mansilla-Polo, Conrad Pujol-Marco, et al.
Dermatology and Therapy|September 25, 2021
Multicenter Retrospective Study of Secukinumab Drug Survival in Psoriasis Patients in a Daily Practice Setting: A Long-Term Experience in SpainEsteban Daudén, Glauber Pacelli Gomes de Lima, Susana Armesto, et al.
Diagnostics (Basel, Switzerland)|March 13, 2025
Advanced Doppler Ultrasound Insights: A Multicenter Prospective Study on Healthy SkinPriscila Giavedoni, Jorge Romaní, Francisco de Cabo, et al.
Dermatologic Therapy|June 22, 2022
Fast and sustained improvement of patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice settingPablo Chicharro, Mar Llamas-Velasco, Susana Armesto, et al.
Bioorganic & Medicinal Chemistry Letters|February 5, 2022
Synthesis and SAR of novel GPR39 agonists and positive allosteric modulatorsRussell Burley, Richard C Hewer, Martin Teall, et al.
Dermatologic Therapy|October 12, 2022
Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patientsPablo Chicharro, Mar Llamas-Velasco, Susana Armesto, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Dermatologic Therapy|September 29, 2022
Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: Multicenter analysis in daily clinical practice by the Spanish Psoriasis GroupVicenç Rocamora, Laura Crespi, Marta Ferran, et al.
International Journal of Molecular Sciences|February 27, 2026
Clinical Characteristics and Gene Expression of JAK2, STAT3, miRNA-155, and miRNA-216a in Young Adults with Acute Ischemic StrokeDavid Vidal-González, Jazmin Marquez-Pedroza, Betsabé Contreras-Haro, et al.
Dermatology and Therapy|April 21, 2026
Real-World Use of Baricitinib in Patients with Atopic Dermatitis in Spain: DAMA-S Study, A Retrospective Chart ReviewEnrique Gómez de la Fuente, Enrique Herrera, Iñigo Martinez-Espronceda Esquerdo, et al.
Dermatologic Therapy|November 25, 2021
Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis GroupElena Del Alcázar, Anna López-Ferrer, Álvaro Martínez-Doménech, et al.
International Journal of Dermatology|May 13, 2024
Certolizumab pegol effectiveness, survival and safety in patients with psoriasis: A multicenter retrospective analysis in daily clinical practice by the Spanish Psoriasis GroupAntonio Sahuquillo-Torralba, Miguel Mansilla-Polo, Conrad Pujol-Marco, et al.
Dermatology and Therapy|September 25, 2021
Multicenter Retrospective Study of Secukinumab Drug Survival in Psoriasis Patients in a Daily Practice Setting: A Long-Term Experience in SpainEsteban Daudén, Glauber Pacelli Gomes de Lima, Susana Armesto, et al.
Diagnostics (Basel, Switzerland)|March 13, 2025
Advanced Doppler Ultrasound Insights: A Multicenter Prospective Study on Healthy SkinPriscila Giavedoni, Jorge Romaní, Francisco de Cabo, et al.
Dermatologic Therapy|June 22, 2022
Fast and sustained improvement of patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice settingPablo Chicharro, Mar Llamas-Velasco, Susana Armesto, et al.
Bioorganic & Medicinal Chemistry Letters|February 5, 2022
Synthesis and SAR of novel GPR39 agonists and positive allosteric modulatorsRussell Burley, Richard C Hewer, Martin Teall, et al.
Dermatologic Therapy|October 12, 2022
Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patientsPablo Chicharro, Mar Llamas-Velasco, Susana Armesto, et al.
Pageof 7